• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Sagimet Biosciences Inc.

    11/14/24 5:05:18 PM ET
    $SGMT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SGMT alert in real time by email
    SC 13G 1 ef20038679_sc13g.htm SC 13G

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549
     

    SCHEDULE 13G
     
    UNDER THE SECURITIES EXCHANGE ACT OF 1934
     
    (Amendment No. )*
     

     
    Sagimet Biosciences Inc.
    (Name of Issuer)
     
    Series A common stock, $0.0001 par value per share
    (Title of Class of Securities)
     
    786700104
    (CUSIP Number)

    September 30, 2024
    (Date of Event Which Requires Filing of this Statement)
     
    Check the Appropriate Box to Designate the Rule Pursuant to Which this Schedule Is Filed:
     
    ☒
    Rule 13d-1(b)
     
    ☐
    Rule 13d-1(c)
     
    ☐
    Rule 13d-1(d)
     
    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
     
    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
     


    1
    NAMES OF REPORTING PERSONS
     
     
    Blue Owl Capital Holdings LP
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
    1,673,877
     
     
     
     
    6
    SHARED VOTING POWER
     
     
    0
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
    1,673,877
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
    0
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    1,673,877
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
    5.46%
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    PN
     
     
     
     
     
    (1) Calculated based on 30,674,855 shares of Series A common stock outstanding as of August 9, 2024, as reported in the Issuer’s report on Form 10-Q filed with the Securities and Exchange Commission on August 14, 2024.


    Item 1(a).
    Name of Issuer

    Sagiment Biosciences Inc.    (the “Issuer”)

    Item 1(b).
    Address of the Issuer’s Principal Executive Offices

    155 Bovet Road, Suite 303,
    San Mateo, California 94402

    Item 2(a).
    Names of Persons Filing

    This statement is filed by the Blue Owl Capital Holdings LP, referred to herein as the “Reporting Person.”

    Item 2(b).
    Address of the Principal Business Office, or if none, Residence

    399 Park Avenue
    New York, New York 10022

    Item 2(c).
    Citizenship

    See response to Item 4 on the cover page.

    Item 2(d).
    Title of Class of Securities

    Series A common stock, $0.0001 par value per share

    Item 2(e).
    CUSIP Number

    786700104

    Item 3.
    If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a(n):

     
    (e)
    ☒ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E)

    Item 4.
    Ownership


    (a)
    Amount beneficially owned:
    See response to Item 9 on the cover page.

     
    (b)
    Percent of Class:
    See response to Item 11 on the cover page.

     
    (c)
    Number of shares as to which the Reporting Person has:

     
    (i)
    Sole power to vote or to direct the vote:
    See response to Item 5 on the cover page.

     
    (ii)
    Shared power to vote or to direct the vote:
    See response to Item 6 on the cover page.

     
    (iii)
    Sole power to dispose or to direct the disposition of:
    See response to Item 7 on the cover page.

     
    (iv)
    Shared power to dispose or to direct the disposition of:
    See response to Item 8 on the cover page.


    The filing of this statement shall not be deemed an admission by the Reporting Person of beneficial ownership of the reported securities for purposes of Section 13(d) or Section 13(g) or any other purpose.

    Item 5.
    Ownership of Five Percent or Less of a Class

    Not Applicable.

    Item 6.
    Ownership of More than Five Percent on Behalf of Another Person

    Not Applicable.

    Item 7
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company

    Not Applicable.

    Item 8.
    Identification and Classification of Members of the Group

    Not Applicable.

    Item 9.
    Notice of Dissolution of Group

    Not Applicable.

    Item 10.
    Certification

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a–11.


    SIGNATURE
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
     
    Dated: November 14, 2024
       
       
     
    BLUE OWL CAPITAL HOLDINGS LP
         
     
    By:
    /s/ Karen Hager
     
    Name: Karen Hager
     
    Title: Chief Compliance Officer

     

    Get the next $SGMT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SGMT

    DatePrice TargetRatingAnalyst
    12/6/2024$30.00Outperform
    Oppenheimer
    11/12/2024$12.00Buy
    UBS
    6/28/2024$23.00 → $6.00Buy → Neutral
    Goldman
    5/2/2024$32.00Buy
    H.C. Wainwright
    3/25/2024$26.00Outperform
    Leerink Partners
    8/8/2023Outperform
    TD Cowen
    8/8/2023$67.00Overweight
    Piper Sandler
    8/8/2023$33.00Buy
    Goldman
    More analyst ratings

    $SGMT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Medical Officer Martins Eduardo Bruno was granted 34,000 units of Series A Common Stock, increasing direct ownership by 42% to 115,213 units (SEC Form 4)

      4 - Sagimet Biosciences Inc. (0001400118) (Issuer)

      2/7/25 4:44:52 PM ET
      $SGMT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President & CEO Happel David was granted 116,000 units of Series A Common Stock, increasing direct ownership by 18% to 755,200 units (SEC Form 4)

      4 - Sagimet Biosciences Inc. (0001400118) (Issuer)

      2/7/25 4:43:56 PM ET
      $SGMT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • General Counsel and CCO Rozek Elizabeth was granted 34,000 units of Series A Common Stock, increasing direct ownership by 21% to 194,506 units (SEC Form 4)

      4 - Sagimet Biosciences Inc. (0001400118) (Issuer)

      2/7/25 4:42:54 PM ET
      $SGMT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SGMT
    SEC Filings

    See more
    • Sagimet Biosciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Sagimet Biosciences Inc. (0001400118) (Filer)

      6/4/25 6:03:02 AM ET
      $SGMT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sagimet Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Sagimet Biosciences Inc. (0001400118) (Filer)

      5/8/25 6:05:59 AM ET
      $SGMT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Sagimet Biosciences Inc.

      10-Q - Sagimet Biosciences Inc. (0001400118) (Filer)

      5/8/25 6:01:10 AM ET
      $SGMT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SGMT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Sagimet Biosciences Inc.

      SC 13G/A - Sagimet Biosciences Inc. (0001400118) (Subject)

      11/14/24 7:55:59 PM ET
      $SGMT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Sagimet Biosciences Inc.

      SC 13G - Sagimet Biosciences Inc. (0001400118) (Subject)

      11/14/24 5:05:18 PM ET
      $SGMT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Sagimet Biosciences Inc.

      SC 13G/A - Sagimet Biosciences Inc. (0001400118) (Subject)

      11/14/24 4:31:38 PM ET
      $SGMT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SGMT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Sagimet Biosciences Announces Positive Phase 3 Results for Denifanstat for the Treatment of Moderate-to-Severe Acne from Partner Ascletis

      Denifanstat met all primary and secondary endpoints versus placebo Denifanstat was well tolerated Oral FASN inhibitors offer a novel mechanism of action for the potential treatment of moderate to severe acne Sagimet initiated first-in-human Phase 1 clinical trial of a second FASN inhibitor, TVB-3567, that is planned to be developed for acne in the U.S. SAN MATEO, Calif., June 04, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today reported denifanstat met all primary and secondary endpoints in a Phase 3 clinical trial for the treatment of

      6/4/25 5:00:00 AM ET
      $SGMT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ascletis Announces Phase III Trial of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne, Meets All Endpoints

      Denifanstat (ASC40), a once-daily oral fatty acid synthase (FASN) inhibitor, demonstrated statistically significant and clinically meaningful improvement compared to placebo in all primary, key secondary, and secondary endpointsDenifanstat demonstrated a favorable safety and tolerability profileDenifanstat was 98% and 178% more effective than U.S. Food and Drug Administration (FDA)-approved sarecycline and doxycycline with regard to placebo-adjusted percent treatment success, respectively, 18.6% for denifanstat versus 9.4% for sarecycline, 18.6% versus 6.7% for doxycyclineDenifanstat was 60% more effective than FDA-approved clascoterone cream with regard to placebo-adjusted percent treatment

      6/3/25 7:15:00 PM ET
      $SGMT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sagimet Biosciences to Host Virtual KOL Event, "Evaluating the Synergistic Potential of a Combination of Denifanstat and Resmetirom for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH)" on May 29, 2025

      SAN MATEO, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced it will host a virtual key opinion leader (KOL) event on Thursday, May 29, 2025 at 1:00 PM ET. To register, click here. The event will feature Rohit Loomba, MD, MHSc (Professor of Medicine, Chief, Division of Gastroenterology and Hepatology, and Director, MASLD Research Center, University of California San Diego), who will join company management to discuss the potential for developing a combination of denifanstat, a fat synthesis inhibitor, with a fat ox

      5/22/25 8:00:00 AM ET
      $SGMT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SGMT
    Financials

    Live finance-specific insights

    See more
    • Sagimet Biosciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

      Denifanstat Phase 2b FASCINATE-2 clinical trial 52-week data was presented in June at the European Association for the Study of the Liver (EASL) Congress Preparations are ongoing to initiate a Phase 3 clinical development program for denifanstat in patients with metabolic dysfunction-associated steatohepatitis (MASH) in the second half of 2024 Two biotechnology industry leaders, Anne Phillips and Jennifer Jarrett, joined the Board of Directors effective August 1, 2024 Anticipated cash runway through 2025 with cash, cash equivalents and marketable securities totaling $188.5 million as of June 30, 2024 SAN MATEO, Calif., Aug. 14, 202

      8/14/24 8:00:00 AM ET
      $SGMT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sagimet Biosciences to Host Conference Call and Webcast to Discuss Recently Presented Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat

      SAN MATEO, Calif., June 10, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. ((Sagimet, NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced that it will host a conference call and webcast on Thursday, June 13, 2024, at 9.30 AM PT / 12:30 PM ET. The event will feature Rohit Loomba, M.D., M.H.Sc., Professor of Medicine, Chief, Division of Gastroenterology and Hepatology, and Director, MASLD Research Center, University of California San Diego, who was the Principal Investigator on the Phase 2b FASCINATE-2 clinical trial and serves as a scientific advi

      6/10/24 8:00:00 AM ET
      $SGMT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SGMT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Happel David bought $63,731 worth of Series A Common Stock (12,100 units at $5.27), increasing direct ownership by 2% to 639,200 units (SEC Form 4)

      4 - Sagimet Biosciences Inc. (0001400118) (Issuer)

      3/28/24 4:08:37 PM ET
      $SGMT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SGMT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $SGMT
    Leadership Updates

    Live Leadership Updates

    See more
    • Oppenheimer initiated coverage on Sagimet Biosciences with a new price target

      Oppenheimer initiated coverage of Sagimet Biosciences with a rating of Outperform and set a new price target of $30.00

      12/6/24 8:14:45 AM ET
      $SGMT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • UBS initiated coverage on Sagimet Biosciences with a new price target

      UBS initiated coverage of Sagimet Biosciences with a rating of Buy and set a new price target of $12.00

      11/12/24 7:50:24 AM ET
      $SGMT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sagimet Biosciences downgraded by Goldman with a new price target

      Goldman downgraded Sagimet Biosciences from Buy to Neutral and set a new price target of $6.00 from $23.00 previously

      6/28/24 8:12:54 AM ET
      $SGMT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sagimet Biosciences Announces Appointment of Thierry Chauche as Chief Financial Officer

      SAN MATEO, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. ((Sagimet, NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced the appointment of Thierry Chauche as Chief Financial Officer, effective today, May 6, 2024. "We are thrilled to welcome Thierry to our executive leadership team in the role of CFO. Thierry brings a proven track record in corporate finance in the biopharmaceutical sector, bringing expertise in corporate planning and strategy, investor relations, financing, and M&A," said Dave Happel, CEO of Sagimet. "Having an

      5/6/24 8:00:00 AM ET
      $SGMT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors

      SAN MATEO, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. ((Sagimet, NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced the appointments of two biotechnology industry leaders, Tim Walbert and Paul Hoelscher, to the board of directors of the Company, effective April 1, 2024. "We are fortunate to have Tim and Paul join us at this key stage as we prepare to initiate a pivotal, Phase 3 trial for our lead candidate denifanstat in MASH in the second half of 2024," said Dave Happel, CEO of Sagimet. "With his experience as CEO of publi

      3/25/24 7:00:00 AM ET
      $IPSC
      $MIRM
      $RPHM
      $SGMT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations